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Abstract 
Xp11.2 translocation renal cell carcinomas
(TRCCs) are a rare family of tumors newly
recognized by the World Health Organization
(WHO) in 2004. These tumors result in the
fusion  of  partner  genes  to  the  TFE3 gene
located on Xp11.2. They are most common in
the  pediatric  population,  but  have  been
recently implicated in adult renal cell carcino-
ma (RCC) presenting at an early age. TFE3-
mediated  direct  transcriptional  upregulation
of the Met tyrosine kinase receptor triggers
dramatic activation of downstream signaling
pathways  including  the  protein  kinase  B
(Akt)/phosphatidylinositol-3  kinase  (PI3K)
and mammalian target of rapamycin (mTOR)
pathways.  Temsirolimus  is  an  inhibitor  of
mammalian  target  of  rapamycin  (mTOR)
kinase, a component of intracellular signaling
pathways involved in the growth and prolifer-
ation of malignant cells. Here we present a
case  of  a  22-year  old  female  who  has  been
treated with temsirolimus for her Xp11.2/TFE3
gene fusion RCC.
Introduction 
Renal cell carcinoma predominantly mani-
fests after the age of 60 with most cases being
sporadic. Most are clear cell carcinomas, with
papillary subtypes representing a minority of
cases.
1 Abnormalities of the Von Hipple Lindau
(VHL) gene are found in 40-50%  of patients
with sporadic RCC, suggesting that the VHL
gene has a role in pathogenesis.
2 The recently
recognized Xp11.2 translocation renal cell car-
cinomas are accepted as a distinctive entity in
the  2004  World  Health  Organization's  renal
tumor  classification.
1 All  bear  gene  fusions
involving the TFE3 transcription factor gene
and comprise approximately one-third of pedi-
atric RCCs.
3Fusion partners for the TFE3 gene
include  the  papillary  renal  cell  carcinoma
(PRCC) gene at 1q21, the  splicing factor PSF
gene at 1p34.1, the splicing factor NonO gene
at Xp12, and the  alveolar soft part sarcoma
(ASPL) gene at 17q25.
3
Prognosis in children with TRCC is difficult
to  ascertain  from  the  literature,  but  would
appear to be favorable for patients with Stage
1-3  surgically  resected  disease  and  unfavor-
able for patients with stage 4 disease.
3-9 The
prognosis  in  adult  onset  translocation  renal
cell carcinoma is especially poor. Argani et al.
analyzed  28  Xp11  translocation  RCCs  in
patients over the age of 20 years.
8 All cases
were  confirmed  by  TFE3  immunohistochem-
istry.  Patients  ranged  in  age  from  22  to  78
years,  with  a  strong  female  predominance
(female:male ratio 22:6).  These cancers tend-
ed to present at advanced stage with 14 of the
28 patients presenting with stage 4 disease.
Lymph  nodes  were  involved  with  metastatic
carcinoma in 11 of 13 cases in which they were
resected.
8 Meyers  et  al. studied  5  cases  of
translocation carcinoma in adult patients, 18
years or older (mean age 32.6 years). Patients
were again diagnosed with advanced disease,
and  most  with  distant  metastases.  Various
treatments met with minimal success. Unlike
pediatric patients, the adult patients followed a
rapidly terminal course, with a mean survival
of 18 months after diagnosis in the 3 patients
with  follow-up  data  (range  10-24  months).
9
Here  we  report  the  successful  treatment  of
adult  onset  TRCC  with  an  inhibitor  of  the
mammalian target of rapamycin.
Case Report 
A 22-year old African American female pre-
sented to our institution with a two month his-
tory  of  hematuria,  lower  extremity  swelling,
and a 25 lbs (11%) weight loss. On physical
examination  she  had  tachycardia,  pale  oral
mucosa, and a palpable mass in the left upper
and lower quadrants of the abdomen.  
A  CT  scan  of  the  abdomen  and  pelvis
revealed a 14x14x20 cm necrotic mass in the
left kidney with extension through the capsule,
tumor invasion into the left renal vein, renal
hilar and celiac lymphadenopathy, and four ill
defined lesions in the right lobe of the liver
measuring 3.3x3.2 cm, 2.4x2.5 cm, 1.6x2.6 cm,
and 2.1x1.8 cm, respectively.  A CT scan of the
chest revealed a 4 mm left lower lobe lung nod-
ule and a small left pleural effusion. A bone
scan and brain MRI were negative for metasta-
sis. A subsequent ultrasound guided biopsy of
the  kidney  revealed  scant  fragments  of  an
epithelioid tumor diagnosed as a renal cell car-
cinoma. Further classification and grading of
the  tumor  were  deferred  to  the  permanent
resection.  The  patient  underwent  an  ultra-
sound guided alcohol embolization of the left
kidney prior to a left nephrectomy, periaortic
lymphadenectomy, and caval thrombectomy. At
the time of nephrectomy, grossly, a 21x13x12.5 cm
mass was noted extending from the hilum of
the  left  kidney  to  the  cortex.  Pathological
examination  of  the  tumor  confirmed  a
21x13x12.5 cm mass which occupied the upper
pole and middle of kidney extending from the
cortex into the renal hilum. The mass grossly
extended  into  the  pelvic  sinus,  involved  the
renal vein and artery, and invaded into the per-
inephric  fat  and  Gerota’s  fascia.  The  tumor
was  a  mostly  solid  red/brown  to  white/tan
mass, with a variegated appearance, showing
areas of hemorrhage and necrosis, as well as
multiple calcified areas. Periaortic lymph node
excision  revealed  that  seven  of  thirty-seven
lymph  nodes  were  involved  with  tumor.  The
liver lesions were not biopsied intraoperative-
ly  due  to  the  highly  vascular  nature  of  the
tumor.  Histopathological  examination  of  the
tumor revealed a renal cell carcinoma with a
heterogeneous appearance consisting of cells
with clear to eosinophilic cytoplasm, arranged
in  nests  and  papillary  cores,  with  extensive
associated  necrosis  and  hemorrhage.
Extensive areas of ossification and focal calci-
fication  were  also  identified.  Immunohisto-
chemical analysis of the primary tumor speci-
men  demonstrated  the  expression  of  the
Xp11.2 translocation/TFE gene fusion product,
with  intense  and  diffuse  positivity.  The  pri-
mary tumor was also focally positive for pan-
cytokeratin, vimentin, CD-10 and negative for
EMA. The final pathological staging reported a
pT3bpN2pMX TRCC, Fuhrman grade G3, with
lymphovascular  invasion.  Surgical  margins
were positive at the renal vein and artery, as
well  as  Gerota’s  fascia.  Unfortunately,  the
patient’s post-operative course was complicat-
ed  by  a  prolonged  hospitalization  due  to  a
wound infection.  
Eight  weeks  post  operatively  the  patient
began chemotherapy with temsirolimus 25 mg
intravenously  every  week.    Before  starting
chemotherapy the patient developed shortness
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doi:10.4081/rt.2009.e53of breath due to a worsening pleural effusion
demonstrated by chest X-ray.  Her pleural effu-
sion  was  presumed  to  be  malignant  from
metastasis from her primary RCC. The patient
unfortunately  declined  a  thoracentesis.  The
patient responded exceptionally well to tem-
sirolimus  clinically  and  her  pleural  effusion
completely resolved on chest X-ray after four
doses  of  temsirolimus.  Significant  clinical
improvement was also noted with an improve-
ment  in  appetite,  weight  gain,  resolution  of
her left flank pain, and a marked improvement
in her overall performance status. 
Unfortunately  after  five  months  of  tem-
sirolimus,  the  patient  demonstrated  disease
progression by CT scanning and recurrence of
her  pleural  effusion.  A  follow-up  CT  scan
revealed  recurrence  of  her  left  pleural  effu-
sion, a hilar mass, subcarinal lymphadenopa-
thy, and too numerous to count liver lesions.
She expired four weeks later after surviving 12
months from the time of diagnosis.  
Discussion 
Translocation renal call carcinomas are usu-
ally  considered  pediatric  carcinomas  with  a
strong  female  predominance.
1-7,10 The  WHO
describes these cancers as papillary renal cell
carcinomas  demonstrating  translocations
involving  the  TFE3 gene  on  chromosome
Xp11.2.  The  histopathological  appearance  is
usually  that  of  a  typical  papillary  carcinoma
with  clear  cells  and  cells  with  granular
eosinophilic  cytoplasm.
1 Early  adult  onset
translocation  RCC  is  associated  with  an
advanced stage at presentation and, most of
the time, with metastatic lesions.
9 A mutated
TFE3 gene leads to upregulation of the mes-
enchymal-epithelial transition (MET) tyrosine
kinase receptor that triggers dramatic activa-
tion of downstream signaling pathways lead-
ing  to  a  neoplastic  cascade  in  normal  cells.
Thus a therapy that blocks this pathway could
represent a reasonable approach to treatment
based on biological rationale.    
The gene of interest, located at Xp11.2, is
TFE3, a member of the microphthalmia tran-
scription factor (MiTF) family. Members of this
family of genes code for basic-helix-loop-helix
leucine-zipper transcription factors that bind
DNA as homodimers or heterodimers. TFE3-
mediated direct transcriptional upregulation of
the Met receptor tyrosine kinase triggers dra-
matic  activation  of  downstream  signaling
pathways.  The depletion of MET by RNA inter-
ference or its functional inhibition by a selec-
tive inhibitor abolishes hepatocyte growth fac-
tor (HGF) stimulated signaling pathways, lead-
ing to loss of various tumorigenic phenotypes
in  TFE3-associated  renal  carcinoma  cells,
including  cell  proliferation,  adhesion,  cell
motility, and matrigel invasion 
11 (Figure 1).  
Many recent publications have linked MET
activation to PI3K/Akt signaling.
12-15 PI3K stim-
ulation leads to the activation of mTOR and
changes  the  translation  rates  of  mRNA
through the intermediates 4E-BP1 and p 70s6k
ribosomal proteins.
13It has been shown in vitro
that PI3K activation by growth factors leads to
Akt dependant phosphorylation of the E3 ubiq-
uitin ligase Mdm2 and degradation of p53.
14 In
vitro data also suggest that inhibition of either
Mdm2  or  mTOR  is  sufficient  to  block  MET
induced cell survival.
13
Temsirolimus is an inhibitor of mammalian
target of rapamycin (mTOR) kinase, a compo-
nent  of  intracellular  signaling  pathways
involved  in  the  growth  and  proliferation  of
cells and the response of such cells to hypoxic
stress.  Temsirolimus  binds  to  an  abundant
intracellular protein, FKBP-12, and in this way
forms a complex that inhibits mTOR signal-
ing.  The disruption of mTOR signaling sup-
presses the production of proteins that regu-
late  progression  through  the  cell  cycle  and
angiogenesis.
15
We believe that our patient’s improvement
with  temsirolimus  is  due  to  its  inhibitory
action on mTOR kinase leading to downregula-
tion  of  cell  proliferation  and  cell  growth
through  two  downstream  pathways:  p70S6K
and 4E-BP1.
14 To date, and to our knowledge,
there has been no prior report of the use of
temsirolimus in Xp11.3/TFE3 fusion transloca-
tion renal cell carcinomas. In our case report
we  showed  resolution  of  a  presumed  malig-
nant  pleural  effusion,  weight  gain,  and  a
marked improvement in the performance sta-
tus  of  the  patient  after  four  doses  of  tem-
sirolimus.  We  hypothesize  that  mTOR
inhibitors interfere with effects of the TFE3
gene  fusion  proteins  leading  to  blockade  of
some of their prooncogenic effects through the
MET receptor tyrosine kinase signaling path-
way. In vitro data suggest that MEK inhibition
enhances rapamycin inhibition of growth in
kidney cancer cell lines,
16 and several trials of
MET  inhibitors  and  mTor  inhibitors  are  in
phase I clinical trials. 
TRCCs are usually identified according to
their distinct morphology, which is that of a
carcinoma  organized  in  nests  and  papillae
lined by clear cells, along with other features
such  as  psammomatous  type  calcifications.
1
Then, usually only in the setting of a pediatric
RCC or an adult who has disease onset at a
young age, are TRCCs suspected and immuno-
histochemical testing for TFE3 carried out.  We
note with interest that several authors have
recently identified TRCCs by TFE3 testing on
unusual clinical presentations of RCC that pre-
sented with classical clear cell histology.
3,5-7,9 If
mTOR/MEK inhibition is proven to be effective
in this subclass of renal cell carcinomas, we
would ask whether TFE3 testing would be war-
ranted in all cases of RCC in younger patients
given the current poor prognosis of patients
presenting with advanced stage disease. 
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